To examine the impact of an intensive HIV preventive intervention (IPI) among female sex workers (FSW) on community HIV transmission, as represented by HIV prevalence among young antenatal clinic (ANC) attenders in Karnataka state, south India.
The IPI was initiated in 18 of the 27 districts in Karnataka in 2003, and was generally at scale by mid-2005, covering over 80% of the urban FSW population. We examined trends over time in HIV prevalence from annual HIV surveillance conducted among ANC attenders in Karnataka under the age of 25 years from 2003 to 2007, comparing the IPI with the other districts.
Overall, HIV prevalence among ANC attenders under 25 years of age declined from 1.40% to 0.77%. In a multivariate model, the decline in HIV prevalence in the IPI districts compared to the other districts was statistically significant (P = 0.01), with an adjusted annual odds ratio of 0.88 (95% CI 0.79–0.97). The decline in standardized HIV prevalence in the IPI districts over the period was 56%, compared to 5% in the non-IPI districts.
Although this analysis is limited by lack of precise comparative data on intervention coverage and intensity, it supports the notion that scaled-up, intensive, targeted HIV preventive interventions among high-risk groups can have a measurable and relatively rapid impact on HIV transmission in the general population, particularly young sexually active populations as represented by ANC attenders. Such focused intervention programmes should be rapidly taken to scale in all HIV epidemics, and especially in concentrated epidemics such as in India.
aDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Canada
bDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Canada
cDepartment of Medicine, University of Manitoba, Winnipeg, Canada
dKarnataka Health Promotion Trust, Bangalore, India
eDepartment of Community Medicine, United Arab Emirates University, Al Ain, United Arab Emirates
fNational AIDS Control Organisation (NACO), New Delhi, India.
Correspondence to Stephen Moses, MD, MPH, Department of Medical Microbiology, University of Manitoba, Room 530, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 0W3. Tel: +1 204 789 3312; fax: +1 204 789 3926; e-mail: email@example.com